exon

<!-- Name:DistributionId Value:8840184 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today…

Confirmed overall response rate improves to 41% at 100mg BID dose level Continued favorable safety and tolerability profile observed in heavily pre-treated patients Pivotal study initiation expected 2H 2022 following food effect study…

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Jan. 25, 2022 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance,…

CLN-081 continues to demonstrate a differentiated clinical profile at the recommended Phase 2 dose of 100mg BID Continued high response rate with favorable safety and tolerability profile observed in heavily pre-treated patients at 100mg…

In vertebrates, large exons often skip splicing events and are evolutionarily conserved. Scientists from Nagoya University, Japan, led by Associate Professor Akio Masuda, have recently identified the mechanism behind regulated splicing of…

- Dystrophin Restoration of 90% of Wild-Type Levels Observed in the Diaphragm and 78% in the Heart with ~80% Dystrophin-Positive Fibers After a Single Dose in mdx Mouse Model - - DYNE-251 Achieves Exon 51 Skipping of 52% in the Diaphragm…

-  Company Anticipates Part B of MOMENTUM to Serve as Pivotal Study for SRP-5051 and to Seek Accelerated Approval if Successful-  Ambulatory and Non-Ambulatory Patients Between the Ages of 7 to 21 Will Be Eligible to Enroll in Part B of…

The FDA approved mobocertinib (Exkivity) as a second-line treatment for locally advanced or metastatic non-small cell lung cancer (NSCLC)…

An oral EGFR/HER2 inhibitor led to high levels of disease control in patients with advanced non-small cell lung cancer (NSCLC) harboring EGFR exon 20 insertion mutations, data from…